Exploring the Role of Nutraceuticals (Red Yeast Rice) in Secondary Prevention: A New Pathway Can Be Opened

Dios, Santiago de; Carrion, Eduardo Fernandez; Makoshi, Javier Antona; Fuertes, Juan J.; Fleites, Hector; Zataraín, Eduardo; Gómez, José Luis Zamorano

doi:10.4236/wjcd.2022.121003

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Social and healthcare interest in prevention has led to a clear increase in their use in recent years, and clinical practice guidelines recognize their growing importance among the available therapeutic options. In fact, the increasingly widespread use of red yeast rice, whose active ingredient is monacolin K, has led to European-wide standardization, limiting its concentration to 2.99 mg [5], [6].…”

Section: Evaluating the Role Of Nutraceuticals In Primary Preventionmentioning

confidence: 99%

Evaluationg the role of Nutraceuticals in Primary Prevention

De Dios,

Fernandez Carrion,

Florido

et al. 2023

EJMED

View full text Add to dashboard Cite

Prevention has become a main factor in the management of cardiovascular diseases. There are many options to control the LDL-Cholesterol levels, which reduction has been widely proved to diminish cardiovascular events rate. Despite the many pharmacological options, an important percentage of the patients do not reach the control target. Among other factors, the available drugs present tolerance problems that limit their use, emerging the necessity to develop new options of treatment that combine efficacy and security. In this field arise the nutraceuticals, which may become an alternative, in selected patients, especially in primary prevention, where the necessity of LDL-cholesterol reduction is not so ambitious, and tolerance and security are essential to achieve the patient adherence to the treatment. The objective of the study is to demonstrate that the new formulation of Lipok®(a nutraceutical based in red yeast rice and berberine) adapting the concentration of monacolines to the new European regulation, is effective in the lipidic profile control. 97 patients in primary prevention that present LDL-Cholesterol levels over the guidelines objective (116mg/dL) where included. Security and effectiveness of adding Lipok® 6 months to the treatment was evaluated. We observed a statistically significant reduction in the TCH values (-34.3mg/dL), LDL-C (-33,8mg/dL) and triglycerides (-29,3mg/dL) at 6 months’ treatment. No variation in the levels of HDL-C was observed. No relevant side effects were reported (constipation <2%, no myalgias). There were mild reductions (that even reached statistical significance) in creatinine, GPT and glycosylated hemoglobin. No patient discontinued treatment in the 6 months. NO patient discontinued the treatment during the study. New formulation of Lipok® has proved to be effective in the control of the LDL-Cholesterol levels without relevant side effects. Considering the significant reduction shown in this study, it may become an alternative to other pharmacological treatments in the management of dyslipidaemia in primary prevention where adherence to the treatment is fundamental.

show abstract

Section: Evaluating the Role Of Nutraceuticals In Primary Preventionmentioning

confidence: 99%